Andrew Guggenhime Vaxcyte, Inc. (PCVX) insider trading activity

Andrew Guggenhime is PRESIDENT AND CFO of Vaxcyte, Inc.. Currently has a direct ownership of 127,173 shares of PCVX, which is worth approximately $4.8 Million. The most recent transaction as insider was on Aug 29, 2022, when has been sold 17,653 shares (Common Stock) at a price of $28.0 per share, resulting in proceeds of $494,284. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 127K

16.15% 3M change

32.92% 12M change

Total Value Held $4.8 Million

ANDREW GUGGENHIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 29 2022	SELL Open market or private sale	$494,284 $28.0 p/Share	17,653 Reduced 29.5%	42,187 Common Stock
Aug 29 2022	BUY Exercise of conversion of derivative security	$94,444 $5.35 p/Share	17,653 Added 22.78%	59,840 Common Stock
Aug 26 2022	SELL Open market or private sale	$36,260 $28.0 p/Share	1,295 Reduced 2.98%	42,187 Common Stock
Aug 26 2022	BUY Exercise of conversion of derivative security	$6,928 $5.35 p/Share	1,295 Added 2.89%	43,482 Common Stock
Aug 25 2022	SELL Open market or private sale	$477,456 $28.0 p/Share	17,052 Reduced 28.79%	42,187 Common Stock
Aug 25 2022	BUY Exercise of conversion of derivative security	$91,228 $5.35 p/Share	17,052 Added 22.35%	59,239 Common Stock
Aug 18 2022	SELL Open market or private sale	$79,081 $25.51 p/Share	3,100 Reduced 6.85%	42,187 Common Stock
Aug 18 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.41%	45,287 Common Stock
Jul 18 2022	SELL Open market or private sale	$76,787 $24.77 p/Share	3,100 Reduced 6.85%	42,187 Common Stock
Jul 18 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.41%	45,287 Common Stock
Jul 08 2022	SELL Open market or private sale	$74,400 $24.0 p/Share	3,100 Reduced 6.85%	42,187 Common Stock
Jul 08 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.41%	45,287 Common Stock
May 18 2022	SELL Open market or private sale	$76,694 $24.74 p/Share	3,100 Reduced 6.85%	42,187 Common Stock
May 18 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.41%	45,287 Common Stock
Apr 18 2022	SELL Open market or private sale	$74,555 $24.05 p/Share	3,100 Reduced 7.09%	40,625 Common Stock
Apr 18 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.62%	43,725 Common Stock
Mar 18 2022	SELL Open market or private sale	$81,003 $26.13 p/Share	3,100 Reduced 7.09%	40,625 Common Stock
Mar 18 2022	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 6.62%	43,725 Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	37,500 Added 48.0%	40,625 Common Stock
Mar 01 2022	SELL Open market or private sale	$148,800 $24.0 p/Share	6,200 Reduced 66.49%	3,125 Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	$33,170 $5.35 p/Share	6,200 Added 39.94%	9,325 Common Stock
Dec 23 2021	SELL Open market or private sale	$74,400 $24.0 p/Share	3,100 Reduced 49.8%	3,125 Common Stock
Dec 23 2021	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 33.24%	6,225 Common Stock
Nov 18 2021	SELL Open market or private sale	$77,035 $24.85 p/Share	3,100 Reduced 49.8%	3,125 Common Stock
Nov 18 2021	BUY Exercise of conversion of derivative security	$16,585 $5.35 p/Share	3,100 Added 33.24%	6,225 Common Stock

Also insider at

MTCR

Metacrine, Inc. Healthcare

Director

CRBU

Caribou Biosciences, Inc. Healthcare

Director